{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:08:03Z","timestamp":1785539283722,"version":"3.56.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ahj.2022.11.003","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T05:48:24Z","timestamp":1668145704000},"page":"25-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy"],"prefix":"10.1016","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-2398","authenticated-orcid":false,"suffix":"Jr","given":"James L.","family":"Januzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrien E.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Marwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Perfetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Urbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2022.11.003_bib0001","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diab Care"},{"key":"10.1016\/j.ahj.2022.11.003_bib0002","doi-asserted-by":"crossref","first-page":"101156","DOI":"10.1016\/j.cpcardiol.2022.101156","article-title":"The pathophysiological basis of diabetic cardiomyopathy development","volume":"47","author":"Avagimyan","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/743503","article-title":"Evidence for a specific diabetic cardiomyopathy: an observational retrospective echocardiographic study in 656 asymptomatic type 2 diabetic patients","volume":"2015","author":"Pham","year":"2015","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0004","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s00125-012-2579-0","article-title":"High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes","volume":"55","author":"Boonman-de Winter","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.ahj.2022.11.003_bib0005","first-page":"00050-6","volume":"S1071-9164","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2022.11.003_bib0006","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"Authors\/Task Force","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2022.11.003_bib0007","article-title":"Complications of diabetes 2017","volume":"2018","author":"Papatheodorou","year":"2018","journal-title":"J Diab Res"},{"issue":"2_suppl","key":"10.1016\/j.ahj.2022.11.003_bib0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications","volume":"26","author":"Dal Canto","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0009","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.11.003_bib0010","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0011","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2021.08.020","article-title":"Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults","volume":"78","author":"Segar","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0012","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2337\/diacare.27.8.1929","article-title":"Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease","volume":"27","author":"Magnusson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2022.11.003_bib0013","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/1741826711420015","article-title":"A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus","volume":"19","author":"Clodi","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0014","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0015","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2362.2011.02539.x","article-title":"Repeat measurements of glycated haemoglobin A(1c) and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus","volume":"41","author":"Neuhold","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ahj.2022.11.003_bib0016","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0017","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1042\/CS20160491","article-title":"Are targeted therapies for diabetic cardiomyopathy on the horizon?","volume":"131","author":"Tate","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ahj.2022.11.003_bib0018","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2022.11.003_bib0019","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10741-012-9313-3","article-title":"Diabetic cardiomyopathy: pathophysiology and clinical features","volume":"18","author":"Miki","year":"2013","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ahj.2022.11.003_bib0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/ars.2009.2502","article-title":"Early neural and vascular dysfunctions in diabetic rats are largely sequelae of increased sorbitol oxidation","volume":"12","author":"Ido","year":"2010","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.ahj.2022.11.003_bib0021","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCRESAHA.109.213447","article-title":"Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model","volume":"106","author":"Ramasamy","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2022.11.003_bib0022","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/diab.46.2.292","article-title":"Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury","volume":"46","author":"Ramasamy","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2022.11.003_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.636267","article-title":"Aldose reductase: an emerging target for development of interventions for diabetic cardiovascular complications","volume":"12","author":"Jannapureddy","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"suppl_1","key":"10.1016\/j.ahj.2022.11.003_bib0024","article-title":"1080-P: addressing the safety challenges of aldose reductase inhibition: development of AT-001 for diabetic cardiomyopathy, a potent and selective next generation aldose reductase inhibitor","volume":"69","author":"Perfetti","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2022.11.003_bib0025","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cardfail.2014.02.007","article-title":"The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota","volume":"20","author":"Dandamudi","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2022.11.003_bib0026","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.pcad.2020.09.006","article-title":"Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure","volume":"63","author":"Singh","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ahj.2022.11.003_bib0027","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1161\/CIRCULATIONAHA.115.017298","article-title":"N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the Atherosclerosis Risk in Communities (ARIC) study","volume":"133","author":"Ndumele","year":"2016","journal-title":"Circulation"},{"issue":"suppl_1","key":"10.1016\/j.ahj.2022.11.003_bib0028","first-page":"A13475","article-title":"Abstract 13475: Clinical assessment of AT-001, an aldose reductase inhibitor in development for diabetic cardiomyopathy: a 28-day proof of concept study","volume":"140","author":"Perfetti","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.11.003_bib0029","unstructured":"<eurjpc0485.pdf>."},{"key":"10.1016\/j.ahj.2022.11.003_bib0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jacc.2014.10.044","article-title":"Exercise limitation associated with asymptomatic left ventricular impairment: analogy with stage B heart failure","volume":"65","author":"Kosmala","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0031","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1161\/CIR.0000000000000483","article-title":"Prioritizing functional capacity as a principal end point for therapies oriented to older adults with cardiovascular disease: a scientific statement for healthcare professionals from the American Heart Association","volume":"135","author":"Forman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.11.003_bib0032","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCHEARTFAILURE.111.965186","article-title":"Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training","volume":"5","author":"Swank","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2022.11.003_bib0033","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jacc.2017.12.048","article-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials","volume":"71","author":"Hicks","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0034","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1161\/CIRCULATIONAHA.106.666818","article-title":"Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology\/American Heart Association heart failure staging criteria in the community","volume":"115","author":"Ammar","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.11.003_bib0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/CIRCOUTCOMES.115.001958","article-title":"Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire","volume":"8","author":"Spertus","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2022.11.003_bib0036","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2022.11.003_bib0037","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2022.11.003_bib0038","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0039","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ahj.2011.07.030","article-title":"Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis","volume":"162","author":"Castagno","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2022.11.003_bib0040","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.11.003_bib0041","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.11.003_bib0042","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.11.003_bib0043","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0044","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4239\/wjd.v10.i10.490","article-title":"Diabetic cardiomyopathy: pathophysiology, theories and evidence to date","volume":"10","author":"Athithan","year":"2019","journal-title":"World J Diab"},{"key":"10.1016\/j.ahj.2022.11.003_bib0045","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2022.11.003_bib0046","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1096\/fj.01-0368fje","article-title":"Aldose reductase activation is a key component of myocardial response to ischemia","volume":"16","author":"Hwang","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.ahj.2022.11.003_bib0047","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0003-2670(97)00649-1","article-title":"Clinical analysis of aldose reductase for differential diagnosis of the pathogenesis of diabetic complication","volume":"365","author":"Tanimoto","year":"1998","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.ahj.2022.11.003_bib0048","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1056\/NEJM197304192881609","article-title":"The sorbitol pathway and the complications of diabetes","volume":"288","author":"Gabbay","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.11.003_bib0049","doi-asserted-by":"crossref","first-page":"61038","DOI":"10.1155\/2007\/61038","article-title":"The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient","volume":"2007","author":"Lorenzi","year":"2007","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.ahj.2022.11.003_bib0050","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1126\/science.2300805","article-title":"Identification of fructose 3-phosphate in the lens of diabetic rats","volume":"247","author":"Szwergold","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ahj.2022.11.003_bib0051","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2337\/diab.35.4.426","article-title":"The effect of oxidation on sorbitol pathway kinetics","volume":"35","author":"Barnett","year":"1986","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2022.11.003_bib0052","doi-asserted-by":"crossref","first-page":"R277","DOI":"10.1152\/ajpregu.00758.2002","article-title":"Vascular NAD(P)H oxidases: specific features, expression, and regulation","volume":"285","author":"Lassegue","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0053","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/diab.42.6.801","article-title":"Hyperglycemic pseudohypoxia and diabetic complications","volume":"42","author":"Williamson","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2022.11.003_bib0054","first-page":"4064","article-title":"Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus","volume":"41","author":"Demaine","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ahj.2022.11.003_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1001-9294(14)60016-X","article-title":"Association of C(-106)T polymorphism in aldose reductase gene with diabetic retinopathy in Chinese patients with type 2 diabetes mellitus","volume":"29","author":"Deng","year":"2014","journal-title":"Chin Med Sci J"},{"key":"10.1016\/j.ahj.2022.11.003_bib0056","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jdiacomp.2017.04.011","article-title":"Association of aldose reductase gene polymorphism (C-106T) in susceptibility of diabetic peripheral neuropathy among north Indian population","volume":"31","author":"Gupta","year":"2017","journal-title":"J Diab Complic"},{"key":"10.1016\/j.ahj.2022.11.003_bib0057","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2337\/diacare.27.8.2021","article-title":"Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes","volume":"27","author":"Sivenius","year":"2004","journal-title":"Diab Care"},{"key":"10.1016\/j.ahj.2022.11.003_bib0058","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/dc08-0712","article-title":"Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients","volume":"31","author":"So","year":"2008","journal-title":"Diab Care"},{"key":"10.1016\/j.ahj.2022.11.003_bib0059","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1464-5491.2006.01946.x","article-title":"Aldose reductase gene is associated with diabetic macroangiopathy in Japanese Type 2 diabetic patients","volume":"23","author":"Watarai","year":"2006","journal-title":"Diab Med"},{"key":"10.1016\/j.ahj.2022.11.003_bib0060","first-page":"H195","article-title":"Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion","volume":"275","author":"Ramasamy","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0061","doi-asserted-by":"crossref","first-page":"H1447","DOI":"10.1152\/ajpheart.2000.279.4.H1447","article-title":"Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury","volume":"279","author":"Tracey","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ahj.2022.11.003_bib0062","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2337\/diacare.27.2.448","article-title":"Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration","volume":"27","author":"Johnson","year":"2004","journal-title":"Diab Care"},{"key":"10.1016\/j.ahj.2022.11.003_bib0063","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/13543776.2019.1582646","article-title":"Aldose reductase inhibitors: 2013-present","volume":"29","author":"Quattrini","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.ahj.2022.11.003_bib0064","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.2337\/dc05-2370","article-title":"Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial","volume":"29","author":"Hotta","year":"2006","journal-title":"Diab Care"},{"key":"10.1016\/j.ahj.2022.11.003_bib0065","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm500907a","article-title":"Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions","volume":"58","author":"Maccari","year":"2015","journal-title":"J Med Chem"},{"issue":"suppl_1","key":"10.1016\/j.ahj.2022.11.003_bib0066","article-title":"379-P: aldose reductase inhibition by AT-001 prevents diabetic cardiomyopathy via reducing myocardial fatty acid oxidation rates","volume":"70","author":"Gopal","year":"2021","journal-title":"Diabetes"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322002873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322002873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:09:13Z","timestamp":1757570953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870322002873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":66,"alternative-id":["S0002870322002873"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2022.11.003","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2022.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}